• 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

Adam Cuker - "Monitoring unfractionated heparin: best practices and controversies"

Dr. Cuker will review evidence, controversies, and best practices in the measurement and monitoring of unfractionated heparin, low molecular weight heparin, and fondaparinux.

Gualtiero Palareti - "Monitoring of direct oral anticoagulants"

Dr. Palareti will review in which circumstances and for which purposes measuring the concentration of the direct oral anticoagulants (DOACs) is indicated and which are the laboratory assays that should be used for this scope and those that are not recommended.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Please note: The course fee is $10.00 in addition to a $2.50 processing fee which is assessed for all electronic registrations.
 
More information and online registration:  http://www.prolibraries.com/isth/
 
 

 
Target audience: 

Clinicaians and laboratory professional involved in the management of patients on anticoagulant therapy

Learning objectives: 

At the conclusion of this activity, I will be able to:

  • Understand the evidence for and against laboratory monitoring of unfractionated heparin.
  • Identify indications for measurement of low molecular weight heparin and fondaparinux.
  • Describe current best practices for monitoring and measurement of unfractionated heparin, low molecular weight heparin, and fondaparinux.
  • Understand the difference between monitoring and measuring anticoagulant agents
  • Learn in which circumstances measuring the concentration of DOACs can help clinical management decisions
  • Understand which are the assays that are recommended to measure the effect of dabigatran, rivaroxaban, apixaban and edoxaban
  • Understand which are the limitations of routine coagulation assays for this scope and why their use is not recommended to measure the anticoagulant effect of DOACs
  • Understand which are the specific effects of DOACs on tests of hemostasis
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
Speakers:
Adam Cuker "Laboratory Measurement of the Heparin-based agents"

Dr. Adam Cuker will review evidence, controversies, and best practices in the measurement and monitoring of unfractionated heparin, low molecular weight heparin, and fondaparinux.

Gualtiero Palareti "Monitoring of direct oral anticoagulants"

Dr. Gualtiero Palareti will review in which circumstances and for which purposes measuring the concentration of the direct oral anticoagulants (DOACs) is indicated and which are the laboratory assays that should be used for this scope and those that are not recommended.

Moderator:

Geoff Barnes

All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  
 

Name

Company

Role

Geoffrey Barnes, MDPortolaConsulting
 Blue Cross Blue Shield of MichiganResearch
 BMS/PfizerResearch
Chris Ward, PhDBayerSpeaker
 Boehringer-IngelheimSpeaker, Advisory Board
 BMS/PfizerSpeaker, Advisory Board
Adam Cuker, MDAmgenConsultant
 GenzymeConsultant
 Bracco Diagnostic ImagingConsultant
Gualtiero Palareti, MDAlfa-WassermannAdvisory Board
 Daiichi-SankyoAdvisory Board
 Instrumentation Laboratory/WerfenSpeaker
 SiemensSpeaker
 StagoSpeaker

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.

CME Coordinator Contact Information

Name: 
Lacey Schmeidler, MA
Phone number: 
+1 (919) 929-3807